KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial.

Junfeng Zhou, Shanshan Li

Int Immunopharmacol 172 116161

PMID41547249
PMCID-
DOI10.1016/j.intimp.2026.116161
发表日期2026-01-17
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

OBJECTIVE: This study aimed to explore the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who had a history of systemic therapies. METHODS: Data were derived from a phase III trial (NCT04839016). This post hoc analysis included patients with moderate-to-severe plaque psoriasis who had a history of systemic therapies, including non-biological systemic therapies (N = 307), biological therapies (N = 32), or both (N = 10), totaling 329 unique patients. Patients were assigned to the vunakizumab (N = 210) and placebo (N = 119) groups according to the treatment regimens. RESULTS: The proportions of patients achieving week (W) 12 Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) responses were higher in the vunakizumab group than in the placebo group (all P > 0.001). These trends were found at most time points over 52 weeks. The median time to achieve PASI 75/90/100 response was 4.4, 8.3, and 16.3 weeks after vunakizumab treatment. Regarding patient-reported outcomes, at W4, W8, and W12, mean Dermatology Life Quality Index (DLQI) and itch numerical rating scale scores were lower, while the proportion of patients achieving DLQI 0/1 response was higher in the vunakizumab group than in the placebo group (P < 0.05). The incidence of any adverse event during the induction period or the entire treatment period was not different between the two groups (P > 0.05). CONCLUSION: Vunakizumab has better efficacy than placebo with satisfactory safety profiles in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。